The estimated Net Worth of Frank R. Oakes is at least 104 千$ dollars as of 11 September 2019. Frank Oakes owns over 1,809 units of Edesa Biotech stock worth over 26,941$ and over the last 9 years Frank sold EDSA stock worth over 77,219$.
Sign up
Frank Oakes EDSA stock SEC Form 4 insiders trading
Frank has made over 5 trades of the Edesa Biotech stock since 2015, according to the Form 4 filled with the SEC. Most recently Frank sold 7,992 units of EDSA stock worth 57,942$ on 18 February 2021.
The largest trade Frank's ever made was selling 7,992 units of Edesa Biotech stock on 18 February 2021 worth over 57,942$. On average, Frank trades about 1,300 units every 118 days since 2015. As of 11 September 2019 Frank still owns at least 6,165 units of Edesa Biotech stock.
You can see the complete history of Frank Oakes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Frank Oakes's mailing address?
Frank's mailing address filed with the SEC is C/O EDESA BIOTECH, INC., 100 SPY COURT, MARKHAM, A6, L3R 5H6.
Insiders trading at Edesa Biotech
Over the last 5 years, insiders at Edesa Biotech have traded over 856,596$ worth of Edesa Biotech stock and bought 247,412 units worth 776,447$ . The most active insiders traders include Der Velden Peter Lumira Cap...、Pardeep Pardeep Nijhawan Me...、Jennifer M Chao. On average, Edesa Biotech executives and independent directors trade stock every 50 days with the average trade being worth of 73,455$. The most recent stock trade was executed by Pardeep Pardeep Nijhawan Me... on 25 March 2024, trading 5,000 units of EDSA stock currently worth 20,000$.
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
What does Edesa Biotech's logo look like?
Complete history of Frank Oakes stock trades at Edesa Biotech
Edesa Biotech executives and stock owners
Edesa Biotech executives and other stock owners filed with the SEC include:
-
Dr. Pardeep Nijhawan FRCPC, M.D.,
CEO, Company Sec. & Director -
Dr. Michael J. Brooks M.B.A., Ph.D.,
Pres -
Kathi Niffenegger CPA, CPA,
Chief Financial Officer -
Rajan Puri,
Sr. VP of Manufacturing -
Gary Koppenjan,
VP of Investor Relations & Communications -
Patrick Marshall,
-
Stephen Lemieux,
Chief Financial Officer -
Joan Chypyha,
-
Charles V Olson,
-
Lorin K Johnson,
-
Carlo Sistilli,
-
Kathi Niffenegger,
Chief Financial Officer -
Der Velden Peter Lumira Cap...,
-
Jennifer M Chao,
-
Frank R. Oakes,
-
Pardeep Pardeep Nijhawan Me...,
Chief Executive Officer -
Paul William Pay,
-
Der Velden Peter Van,
-
Sean Arthur Mac Donald,
-
Michael J Brooks,
President -
Pardeep Nijhawan,
Chief Executive Officer